Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Text Size

EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients (EBVER/TMC)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Andreas Arnold, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01942005
First received: August 7, 2013
Last updated: December 3, 2014
Last verified: December 2014
History of Changes
  Purpose
Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

Condition
Immunosuppression
Neoplasm

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection

Further study details as provided by University Hospital, Basel, Switzerland:

Primary Outcome Measures:
  • Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen. [ Time Frame: 7 years ]

Secondary Outcome Measures:
  • correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [ Time Frame: 7 years ]

Biospecimen Retention:   Samples With DNA
Blutsample

Enrollment: 144
Study Start Date: January 2010
Study Completion Date: May 2014
Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
Detailed Description:
correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.
  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients who underwent organ transplatation or patients who have a HIV infection
Criteria

Inclusion Criteria:

  • patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion Criteria:

  • written informed consent not given
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01942005

Locations
Switzerland
University Hospital Basel, Dermatology
Basel, Basel Stadt, Switzerland, 4031
Sponsors and Collaborators
Andreas Arnold
Investigators
Principal Investigator: Andreas Arnold, MD University Hospital Basel, Dermatology, CH-4031 Basel
  More Information

Responsible Party: Andreas Arnold, Dr. med. Andreas Arnold, senior physician, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier: NCT01942005     History of Changes
Other Study ID Numbers: 11/10
Study First Received: August 7, 2013
Last Updated: December 3, 2014

ClinicalTrials.gov processed this record on May 25, 2017